Mandate

Vinge advises Stadsnätsbolaget Sverige AB in an innovative infrastructure transaction

June 27, 2017

Vinge has advised Stadsnätsbolaget Sverige AB (”Stadsnätsbolaget”) in conjunction with its sale of five fibre networks in Eskilstuna, Strängnäs, Salem, Haninge and Södertälje to a start-up company (Fibernät i Mellansverige AB) which is owned and managed by Pareto Business Management AB.


The fibre network provides approximately 10 000 households in Central Sweden with internet connections. The acquisition is a so called sale and leaseback where the fibre network is sold, but is thereafter conducted and maintained by Stadsnätsbolaget. The transaction is an innovative financing arrangement which gives Stadsnätsbolaget the possibility to continue to invest and further develop fibre networks in Sweden.

Vinge’s team consisted of responsible partner Jonas Bergström and associate Alex Miler. Partner Assur Badur and associate Frida Ställborn provided real estate law advice.

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026